Jump to content

Terbequinil

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by BsherrAWBBOT (talk | contribs) at 22:20, 28 July 2020 (orphaning per Wikipedia:Templates for discussion/Log/2020 July 17#Template:Nootropics, plus general fixes). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Terbequinil
Ball-and-stick model of the terbequinil molecule
Clinical data
ATC code
  • none
Identifiers
  • 1-(methoxymethyl)-4-oxo-N-propylquinoline-3-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H18N2O3
Molar mass274.320 g·mol−1
3D model (JSmol)
  • CCCNC(=O)C1=CN(C2=CC=CC=C2C1=O)COC
  • InChI=1S/C15H18N2O3/c1-3-8-16-15(19)12-9-17(10-20-2)13-7-5-4-6-11(13)14(12)18/h4-7,9H,3,8,10H2,1-2H3,(H,16,19) checkY
  • Key:RIPDGZHPNKQLDC-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Terbequinil (SR-25776) is a stimulant and nootropic drug which acts as a partial inverse agonist at benzodiazepine sites on the GABAA receptor. In human trials it was found to partially reverse the sedative and amnestic effects of the hypnotic drug triazolam with only slight effects when administered by itself.[1]

See also

References

  1. ^ Warot D, Danjou P, Douillet P, Keane P, Puech AJ (1994). "Cognitive impairments induced by triazolam in healthy volunteers: antagonism by a partial inverse agonist of benzodiazepine receptor". Therapie. 49 (1): 23–6. PMID 8091361.